Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma

Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma

<i>Objective:</i> Hepatocellular carcinoma (HCC) is frequently diagnosed in patients with late-stage disease who are ineligible for curative surgical therapies. The majority of patients become resistant to sorafenib, the only approved first-line therapy for advanced cancer, underscoring...

Full description

Bibliographic Details
Main Authors: Kelly Regan-Fendt, Ding Li, Ryan Reyes, Lianbo Yu, Nissar A. Wani, Peng Hu, Samson T. Jacob, Kalpana Ghoshal, Philip R.O. Payne, Tasneem Motiwala
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cancers
Subjects:
hepatocellular carcinoma
drug resistance
drug repurposing
sorafenib
fostamatinib
dasatinib
Online Access:https://www.mdpi.com/2072-6694/12/10/2730

Similar Items

Similar Items